Affinity Asset Advisors
SLDB icon

Affinity Asset Advisors’s Solid Biosciences SLDB Stock Holding History

Affinity Asset Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.89M Buy
+400,000
New +$3.62M 0.12% 102

Other funds holding SLDB

SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Affinity Asset Advisors's SLDB Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in Solid Biosciences (SLDB) in Q3 2026: 400,000 shares worth $2.89M. The stake represents 0.12% of the portfolio and ranks #102 among its holdings.

99 funds tracked by Wall St. Rank hold SLDB as of Q3 2026.

  • Affinity Asset Advisors held 400,000 shares of Solid Biosciences worth $2.89M as of Q3 2026.
  • Solid Biosciences was a new Affinity Asset Advisors position in Q3 2026.
  • Solid Biosciences made up 0.12% of Affinity Asset Advisors's portfolio in Q3 2026, its #102 holding.
  • 99 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.